Table 1.
Demographic and baseline characteristics of total sample.
| Total sample (n = 200) | Yoga (n = 100) | Wait-list (n = 100) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Variable | n | % | M | (SD) | n | % | M | (SD) | n | % | M | (SD) |
| Age (years) | 51.6 | (9.2) | 51.8 | (9.8) | 51.3 | (8.7) | ||||||
| BMI (kg/m2) | 27.8 | (5.7) | 27.9 | (5.3) | 27.6 | (6.0) | ||||||
| BCPT cognitive problems | 1.5 | (1.0) | 1.5 | (1.0) | 1.4 | (1.0) | ||||||
| CES-D depressive symptoms | 10.7 | (8.2) | 10.2 | (8.2) | 11.2 | (8.2) | ||||||
| BAI anxiety symptoms | 10.1 | (7.1) | 9.8 | (7.2) | 10.33 | (7.1) | ||||||
| SF-36 vitality | 46.5 | (20.6) | 48.6 | (20.2) | 44.4 | (20.9) | ||||||
| PSQ sleep quality | 7.5 | (3.5) | 7.9 | (3.9) | 7.2 | (3.1) | ||||||
| CHAMPS moderate-to-high intensity activity, hrs/week | 6.3 | (5.8) | 6.8 | (6.3) | 5.8 | (5.1) | ||||||
| Race/Ethnicity | ||||||||||||
| White | 176 | 88.5 | 88 | 88 | 88 | 88 | ||||||
| Black | 18 | 9 | 8 | 8 | 10 | 10 | ||||||
| Asian | 5 | 2.5 | 3 | 3 | 2 | 2 | ||||||
| Marital Status | ||||||||||||
| Single | 26 | 13 | 18 | 18 | 8 | 8 | ||||||
| Married | 140 | 70 | 68 | 68 | 72 | 72 | ||||||
| Separated/divorced | 29 | 14.5 | 14 | 14 | 15 | 15 | ||||||
| Widowed | 5 | 2.5 | 0 | 0 | 5 | 5 | ||||||
| Education level | ||||||||||||
| High school or less | 12 | 6 | 5 | 5 | 7 | 7 | ||||||
| Some college | 49 | 24.5 | 27 | 27 | 22 | 22 | ||||||
| College graduate | 62 | 31 | 29 | 29 | 33 | 33 | ||||||
| Postgraduate | 77 | 38.5 | 39 | 39 | 38 | 38 | ||||||
| Employment status | ||||||||||||
| Employed | 137 | 68.5 | 71 | 71 | 66 | 66 | ||||||
| Unemployed | 35 | 17.5 | 15 | 15 | 20 | 20 | ||||||
| Retired | 28 | 14 | 14 | 14 | 14 | 14 | ||||||
| Income level ($) | ||||||||||||
| 0 – 25,000 | 10 | 5.5 | 3 | 3 | 7 | 7 | ||||||
| 25,000 – 50,000 | 33 | 18 | 18 | 18 | 15 | 15 | ||||||
| 50,000 – 75,000 | 35 | 19.1 | 17 | 17 | 18 | 18 | ||||||
| 75,000-100,000 | 46 | 25.1 | 23 | 23 | 23 | 23 | ||||||
| >100,000 | 59 | 32.2 | 30 | 30 | 29 | 29 | ||||||
| No report | 17 | 8 | 9 | 9 | 8 | 8 | ||||||
| Type of treatment | ||||||||||||
| Surgery only | 26 | 13 | 13 | 13 | 13 | 13 | ||||||
| Surgery plus radiation | 52 | 26 | 28 | 28 | 24 | 24 | ||||||
| Surgery plus chemotherapy | 46 | 23 | 23 | 23 | 23 | 23 | ||||||
| Surgery plus radiation plus chemotherapy | 76 | 38 | 36 | 36 | 40 | 40 | ||||||
| Cancer stage at diagnosis | ||||||||||||
| 0 | 18 | 9 | 9 | 9 | 9 | 9 | ||||||
| I | 89 | 44.5 | 46 | 46 | 43 | 43 | ||||||
| IIA | 52 | 26 | 27 | 27 | 25 | 25 | ||||||
| IIB | 23 | 11.5 | 10 | 10 | 13 | 13 | ||||||
| IIIA | 18 | 9 | 8 | 8 | 10 | 10 | ||||||
| Tamoxifen/aromatase inhibitor use | 143 | 71.5 | 72 | 72 | 71 | 71 | ||||||
| Postmenopausal | 153 | 81 | 76 | 76 | 77 | 77 | ||||||
| Time since diagnosis (months) | 17.3 | (8.1) | 16.3 | (7.5) | 18.3 | (8.5) | ||||||
| Time since treatment (months) | 10.9 | (7.9) | 9.9 | (7.1) | 11.8 | (8.5) | ||||||